early-stage lung adenocarcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient aged 20–79 years old, both male or female; 2. Tumor size = 0.25); 5. Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative ( 1.5L or FEV1% >= 70%); 8. Eastern Cooperative Oncology Group, 0 to 2; 9. Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.
Exclusion criteria
Exclusion criteria: 1. Radiological pure ground glass nodules (consolidation to tumor ratio 5%); 4. Intraoperative frozen section confirmed adenocarcinoma in situ andminimally invasive adenocarcinoma; 5. Preoperative imaging examination or EBUS indicated lymph node positive metastasis; 6. preoperative imaging examination revealed distant metastasis; 7. Patients with severe damage to heart, liver and kidney function (grade 3 ~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit); 8. Patients with other malignant tumors; 9. Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy); 10. Non prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects; 11. Those who have participated in other tumor-related clinical trials within three months; 12. Those are not suitable for participating in trials according to investigator's assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate;Reduced pulmonary function after surgery;Incidence rate of perioperative mortality and complication; | — |
Countries
China
Contacts
Shanghai Pulmonary Hospital